Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
Bertrand RoutyGustave Roussy Cancer Campus (GRCC), Villejuif, FranceEmmanuelle Le ChatelierMGP MetaGénoPolis, INRA, Université Paris-Saclay, Jouy-en-Josas, FranceLisa DerosaGustave Roussy Cancer Campus (GRCC), Villejuif, FranceConnie P.M. DuongCenter of Clinical Investigations in Biotherapies of Cancer (CICBT) 1428, Villejuif, FranceMaryam Tidjani AlouGustave Roussy Cancer Campus (GRCC), Villejuif, FranceRomain DaillèreGustave Roussy Cancer Campus (GRCC), Villejuif, FranceAurélie FluckigerCenter of Clinical Investigations in Biotherapies of Cancer (CICBT) 1428, Villejuif, FranceMeriem MessaoudeneGustave Roussy Cancer Campus (GRCC), Villejuif, FranceConrad RauberGustave Roussy Cancer Campus (GRCC), Villejuif, FranceMaría Paula RobertiCenter of Clinical Investigations in Biotherapies of Cancer (CICBT) 1428, Villejuif, FranceMarine FidelleCenter of Clinical Investigations in Biotherapies of Cancer (CICBT) 1428, Villejuif, FranceCaroline FlamentCenter of Clinical Investigations in Biotherapies of Cancer (CICBT) 1428, Villejuif, FranceVichnou Poirier-ColameCenter of Clinical Investigations in Biotherapies of Cancer (CICBT) 1428, Villejuif, FrancePaule OpolonGustave Roussy, Laboratoire de Pathologie Expérimentale, 94800 Villejuif, FranceChristophe KleinCentre de Recherche des Cordeliers, INSERM, Université Paris Descartes, Sorbonne Paris Cité, UMRS 1138, Université Pierre et Marie Curie Université Paris 06, Sorbonne Universités, Paris, FranceKristina IribarrenEquipe 11 Labellisée–Ligue Nationale contre le Cancer, Centre de Recherche des Cordeliers, Paris, FranceLaura MondragónEquipe 11 Labellisée–Ligue Nationale contre le Cancer, Centre de Recherche des Cordeliers, Paris, FranceNicolas JacquelotGustave Roussy Cancer Campus (GRCC), Villejuif, FranceBo QuGustave Roussy Cancer Campus (GRCC), Villejuif, FranceGladys FerrereGustave Roussy Cancer Campus (GRCC), Villejuif, FranceCéline ClémensonDepartment of Radiation Oncology, INSERM U1030, and Molecular Radiotherapy, Gustave Roussy, Université Paris-Saclay, F-94805 Villejuif, FranceLaura MezquitaDepartment of Medical Oncology, Gustave Roussy, Villejuif, FranceJ. Remon MasipDepartment of Medical Oncology, Gustave Roussy, Villejuif, FranceCharles NaltetThoracic Oncology Department–CIC1425/CLIP2 Paris-Nord, Hospital Bichat-Claude Bernard, AP-HP, Université Paris-Diderot, Paris, FranceSolenn BrosseauThoracic Oncology Department–CIC1425/CLIP2 Paris-Nord, Hospital Bichat-Claude Bernard, AP-HP, Université Paris-Diderot, Paris, FranceCourèche KaderbhaïDepartment of Medical Oncology, Center GF Leclerc, Dijon, FranceCorentin RichardDepartment of Medical Oncology, Center GF Leclerc, Dijon, FranceHira RizviDruckenmiller Center for Lung Cancer Research, Memorial Sloan Kettering Cancer Center, New York, NY, USAFlorence LevenezMGP MetaGénoPolis, INRA, Université Paris-Saclay, Jouy-en-Josas, FranceNathalie GalleronMGP MetaGénoPolis, INRA, Université Paris-Saclay, Jouy-en-Josas, FranceBenoît QuinquisMGP MetaGénoPolis, INRA, Université Paris-Saclay, Jouy-en-Josas, FranceNicolas PonsMGP MetaGénoPolis, INRA, Université Paris-Saclay, Jouy-en-Josas, FranceBernhard RyffelMolecular Immunology and Embryology, UMR 7355, CNRS, University of Orleans, Orléans, FranceVéronique Minard-ColinDepartment of Pediatric Oncology, GRCC, Villejuif, FrancePatrick GoninGustave Roussy Cancer Campus (GRCC), Villejuif, FranceJean‐Charles SoriaDepartment of Medical Oncology, Gustave Roussy, Villejuif, FranceÉric DeutschDepartment of Radiation Oncology, INSERM U1030, and Molecular Radiotherapy, Gustave Roussy, Université Paris-Saclay, F-94805 Villejuif, FranceYohann LoriotDepartment of Medical Oncology, Gustave Roussy, Villejuif, FranceFrançois GhiringhelliDepartment of Medical Oncology, Center GF Leclerc, Dijon, FranceGérard ZalcmanThoracic Oncology Department–CIC1425/CLIP2 Paris-Nord, Hospital Bichat-Claude Bernard, AP-HP, Université Paris-Diderot, Paris, FranceFrançois GoldwasserDepartment of Medical Oncology, Cochin Hospital, Assistance Publique–Hôpitaux de Paris, Paris, FranceBernard EscudierDepartment of Medical Oncology, Gustave Roussy, Villejuif, FranceMatthew D. HellmannDepartment of Medicine, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY, USAAlexander EggermontDepartment of Medical Oncology, Gustave Roussy, Villejuif, FranceDidier RaoultURMITE, Aix Marseille Université, UM63, CNRS 7278, IRD 198, INSERM 1095, IHU–Méditerranée Infection, 13005 Marseille, FranceLaurence AlbigèsDepartment of Medical Oncology, Gustave Roussy, Villejuif, FranceGuido KroemerEquipe 11 Labellisée–Ligue Nationale contre le Cancer, Centre de Recherche des Cordeliers, Paris, FranceLaurence ZitvogelCenter of Clinical Investigations in Biotherapies of Cancer (CICBT) 1428, Villejuif, France
2017en
ABI
Аннотация
Good bacteria help fight cancer Resident gut bacteria can affect patient responses to cancer immunotherapy (see the Perspective by Jobin). Routy et al. show that antibiotic consumption is associated with poor response to immunotherapeutic PD-1 blockade. They profiled samples from patients with lung and kidney cancers and found that nonresponding patients had low levels of the bacterium Akkermansia muciniphila . Oral supplementation of the bacteria to antibiotic-treated mice restored the response to immunotherapy. Matson et al. and Gopalakrishnan et al. studied melanoma patients receiving PD-1 blockade and found a greater abundance of “good” bacteria in the guts of responding patients. Nonresponders had an imbalance in gut flora composition, which correlated with impaired immune cell activity. Thus, maintaining healthy gut flora could help patients combat cancer. Science , this issue p. 91 , p. 104 , p. 97 ; see also p. 32
Перевод пока недоступен
Идентификаторы
Цитирования и источники
Цитирований: 5Использованных источников: 0